Outcomes of patients with Killip class III acute myocardial infarction after primary percutaneous coronary

Tzu-Hsien Tsai1, Sarah Chua, Hisham Hussein

  • 1Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan, Republic of China.

Critical Care Medicine
|January 19, 2011
PubMed

Insights

Patients with Killip class III acute ST-segment elevation myocardial infarction (STEMI) face significantly higher mortality risks, even after primary percutaneous coronary intervention. Killip III status is an independent predictor of both 30-day and 1-year mortality in STEMI patients.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Acute Myocardial Infarction Research

Background:

  • Outcomes for patients with Killip class III acute ST-elevation myocardial infarction (STEMI) in the reperfusion era are not well-established.
  • Primary percutaneous coronary intervention (PCI) is a standard treatment for STEMI, but its impact on high-risk patient subgroups requires further investigation.

Purpose of the Study:

  • To investigate the short- and long-term outcomes of patients with Killip class III STEMI who underwent primary PCI.
  • To determine if Killip class III remains an independent predictor of mortality in the current treatment paradigm.

Main Methods:

  • A prospective study of 1,278 consecutive STEMI patients undergoing primary PCI between January 2002 and November 2009.
  • Patients were categorized into Killip class I (n=832), II (n=216), and III (n=230) based on presentation.
  • Outcomes including angiographic findings, in-hospital complications, and 30-day and 1-year mortality were analyzed.

Main Results:

  • Killip III patients had significantly lower final thrombolysis in myocardial infarction (TIMI) 3 flow and higher incidence of multi-vessel disease compared to Killip I and II.
  • The incidence of advanced congestive heart failure during hospitalization was substantially higher in Killip III patients (71.3%).
  • 30-day mortality (20.0%) and 1-year cumulative mortality (31.7%) were significantly higher in Killip III patients, who were independently predicted by this classification.

Conclusions:

  • Killip class III remains a strong and independent predictor of 30-day and 1-year mortality in STEMI patients, despite undergoing primary PCI.
  • These findings highlight the critical need for aggressive management and closer monitoring of STEMI patients presenting with Killip class III.
  • Further research may explore novel therapeutic strategies to improve outcomes in this high-risk population.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Endocarditis IV: Nursing Management01:29

Endocarditis IV: Nursing Management

Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...